India Pharma Outlook Team | Tuesday, 06 October 2026
Bold platform plays and pipeline moves define the day as major drugmakers race to control the tools that will shape tomorrow’s medicines and diagnostics.
Eli Lilly doubles down on Gate Bioscience to open molecular gates against proteins that once seemed impossible to drug with oral pills.
At the same time, GE HealthCare spends USD 945 million to buy Sofie Biosciences and secure PET imaging agents plus a ready U.S. manufacturing network.
SPARC’s quiet tax win adds fresh support for domestic research capacity. These parallel bets show big players racing to own the next generation of tools focused on oral small molecules, while others focus on radiopharmaceuticals. All while tightening their grip on discovery engines and supply chains.
Lilly expands its alliance with Gate Bioscience by adding one new undisclosed target and keeping the door open for a second. The multi-year deal puts more than USD 870 million in potential payments on the table.
Gate receives an undisclosed upfront sum, another payment if the partners choose a second target, milestone cash for preclinical, clinical, and commercial progress, and tiered royalties on future sales. Gate’s Molecular Gate engine creates oral small-molecule drugs that eliminate hard-to-reach extracellular proteins.
The company sees about 4,000 such targets, many of them high-value opportunities in immunology, neuroscience, and cardiometabolic health that still lack good treatment options or force patients to rely on injectables. Gate leads the discovery work. Lilly takes exclusive worldwide rights to develop and commercialize the resulting medicines from later preclinical stages onward.
Gate CEO Jordi Mata-Fink highlights how the earlier collaboration already proves the engine can deliver selective molecular gates, with Lilly’s expertise speeding everything up. This marks Lilly's second major commitment, after partnering with Gate in July 2025 for up to USD 856 million and later investing in the biotech’s USD 65 million Series B round.
Also Read: Building Scalable MedTech Ecosystem for India's Healthcare Future
GE HealthCare moves just as decisively on the radiopharma front. The company agrees to buy privately held Sofie Biosciences for USD 945 million in cash. The purchase hands GE U.S. rights to FAPI-74, an experimental PET imaging agent now in late-stage testing that could help detect several types of cancer. GE already owns rights to the same agent outside the United States.
Sofie develops radioisotopes used in PET scans and runs facilities that manufacture and distribute them to hospitals and imaging centers. After the deal closes in the first half of 2027, Sofie will keep making products for its existing customers, including other radiopharma companies.
The acquisition strengthens GE’s pharmaceutical diagnostics business by pairing new agents with its imaging systems and expanding its reach in the fast-growing radiopharmaceuticals market.
The timing fits a broader wave of activity. Curium struck a deal worth up to USD 8 billion for Lantheus earlier this year, and GE itself bought imaging software firm Intelerad for USD 2.3 billion in March. GE’s current radiopharma lineup already includes Flyrcado, an FDA-approved PET agent for detecting coronary artery disease and related heart conditions.
While the big deals grab headlines, SPARC delivers a quieter but useful win. The Customs, Excise and Service Tax Appellate Tribunal in Mumbai dismisses the Revenue Department’s appeal and upholds SPARC’s right to Rs 27.51-crore refund of accumulated CENVAT credit plus interest.
SPARC develops new molecules and drug delivery systems that it out-licenses to other companies. The ruling clears a long-running tax dispute and frees up resources that can support ongoing research.
These three developments share a clear pattern. Large companies no longer settle for simple pipeline deals. They now lock in the platforms that create new drug classes and the manufacturing networks that deliver them.
Together, the moves show pharma giants actively securing the tools, talent, and infrastructure they need for the next wave of medicines and diagnostics. The race to own platforms and pipelines is fully underway.
.jpg)
